Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0KQ0C
|
|||
| Former ID |
DNCL001805
|
|||
| Drug Name |
Danegaptide
|
|||
| Synonyms |
SCHEMBL2399760; BCP17534; ZP 1609
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Atrial fibrillation [ICD-11: BC81.3; ICD-10: I48] | Phase 2 | [1] | |
| Company |
Pfizer; Zealand Pharma
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C14H17N3O4
|
|||
| Canonical SMILES |
C1C(CN(C1C(=O)O)C(=O)CN)NC(=O)C2=CC=CC=C2
|
|||
| InChI |
1S/C14H17N3O4/c15-7-12(18)17-8-10(6-11(17)14(20)21)16-13(19)9-4-2-1-3-5-9/h1-5,10-11H,6-8,15H2,(H,16,19)(H,20,21)/t10-,11+/m1/s1
|
|||
| InChIKey |
BIZKIHUJGMSVFD-MNOVXSKESA-N
|
|||
| CAS Number |
CAS 943134-39-2
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Gap junction protein (GJP) | Target Info | Modulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01977755) Phase 2 Clinical Proof-of-Concept Study of the Cardioprotective Properties of Danegaptide in ST Segment Elevation Myocardial Infarction. U.S. National Institutes of Health. | |||
| REF 2 | The gap junction modifier, GAP-134 [(2S,4R)-1-(2-aminoacetyl)-4-benzamido-pyrrolidine-2-carboxylic acid], improves conduction and reduces atrial fibrillation/flutter in the canine sterile pericarditis model. J Pharmacol Exp Ther. 2009 Jun;329(3):1127-33. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.